Omniox, an NCI SBIR-funded company, is an IND stage biotherapeutics company developing products that focus on hypoxic microenvironments in cancer, tissue ischemia, and critical care. Omniox is currently funded by The Wellcome Trust and the National Cancer Institute to develop its lead product, OMX-4.80P, to treat a range of hypoxic tumors in combination with chemoradiotherapy. The company is developing a second OMX product to treat focal tissue ischemia resulting from vaso-occlusions with the goal of saving tissue and preserving long-term organ function. The same product is effective in preventing heart failure in cases of acute global hypoxia. Omniox is evaluating financing and partnering options that support the initiation of multiple Phase 2 clinical programs by 2017.